ARENA PHARMACEUTICALS INC 4
4 · ARENA PHARMACEUTICALS INC · Filed Sep 11, 2013
Insider Transaction Report
Form 4
BEHAN DOMINIC P
DirectorSVP & Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2013-09-10$1.49/sh+150,000$223,500→ 603,000 total - Exercise/Conversion
Common Stock
2013-09-10$1.81/sh+50,000$90,500→ 653,000 total - Sale
Common Stock
2013-09-10$6.31/sh−200,000$1,261,020→ 453,000 total - Exercise/Conversion
Employee Stock Option (right to buy)
2013-09-10−150,000→ 150,000 totalExercise: $1.49Exp: 2021-03-15→ Common Stock (150,000 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2013-09-10−50,000→ 450,000 totalExercise: $1.81Exp: 2022-03-19→ Common Stock (50,000 underlying)
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $6.26 and $6.34 per share, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The options vest in four equal annual installments, and are exercisable once vested. The first and second installments became exercisable on March 15, 2012, and 2013, and the third and fourth installments vest on March 15, 2014, and 2015.
- [F4]The options vest in four equal annual installments, and are exercisable once vested. The first installment became exercisable on March 19, 2013, and the second, third and fourth installments vest on March 19, 2014, 2015 and 2016.